aspirin / Generic mfg. - LARVOL DELTA

Abstract: Maternal and fetal outcomes of pregnancy in essential thrombocythemia: A systematic review. (ASH 2025) - "Eligible studies were retrospective cohort studies and case reports of pregnant women with ET receiving aspirin (ASA), interferon (IFN), low-molecular weight heparin (LMWH), or no treatment...This would improve patient-cantered outcomes as well as aid in investigation of population-specific risk factors and the socio-economic factors influencing pregnancy outcomes in ET. The complexity of ET in pregnancy and pregnancy planning, necessitates comprehensive, collaborative cross-disciplinary care and research."

Review • Cardiovascular • Essential Thrombocythemia • Hematological Disorders • Myeloproliferative Neoplasm • Obstetrics • Thrombocytosis • Thrombosis

Outcomes of venous thromboembolism in multiple myeloma: A nationwide analysis of anticoagulation strategies (ASH 2025) - "The current guideline from ASH has a conditional recommendation regarding the use of anticoagulation for VTE prophylaxis in ambulatory patients with MM receiving lenalidomide-, thalidomide-, or pomalidomide-based regimens. Conclusion MM patients who developed VTE without any prophylactic antithrombotic therapy experienced worse outcomes, including longer hospitalizations, higher healthcare costs, and increased mortality. Use of aspirin or anticoagulants was associated with improved clinical outcomes, underscoring the importance of reinforcing thromboprophylaxis in MM patients."

Cardiovascular • Hematological Malignancies • Multiple Myeloma • Venous Thromboembolism

Risk stratification, prognostic factors, outcomes and quality of life assessment in patients with primary polycythemia (ASH 2025) - "Therapeutic modalities used at our center included phlebotomy in 91.5%, aspirin in 80.5%, cytoreduction with hydroxyurea in 25.4% and systemic anticoagulation in 11% of patients. Our study provides a valuable insight into the prognostic factors and disease process of PV and JAK2 unmutated erythrocytosis in the Indian population. It also gives a glimpse of the QoL in this population, which has till date never been explored before. With such significant divergence from global standards, it is integral to explore these in much greater detail to understand its intricacies in our large and diverse subpopulation."

Biomarker • Clinical • HEOR • Cardiovascular • Chronic Eosinophilic Leukemia • Diabetes • Dyslipidemia • Fibrosis • Hematological Disorders • Hypertension • Metabolic Disorders • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombosis • JAK2

Modifiable lifestyle factors in patients with myeloproliferative neoplasms in the California teachers study (ASH 2025) - "While interventions such as therapeutic phlebotomy, aspirin, and cytoreductive therapy are helpful thrombotic risk reduction strategies, modification of cardiovascular risk factors is also recommended... The California Teacher Study MPN cohort offers longitudinal insight into the modifiable lifestyle behaviors of female patients afflicted with MPNs in California. More than a third of the cohort is overweight or obese (39.4%), suggesting weight management programs may be particularly important in this population. Alcohol consumption is present in 59.5% of the participants, which may contribute to inflammatory and thrombotic complications in MPN, suggesting that cessation may be an important modifiable risk factor in this cohort."

Clinical • Cardiovascular • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Obesity • Polycythemia Vera • Thrombocytopenia

Application of polycythemia vera guidelines in pediatric patient with erythrocytosis: A case series (ASH 2025) - "He has been treated with aspirin and phlebotomy with significant symptom improvement...Applying adult guidelines for treatment did not show significant hematologic improvement, although symptom relief was observed in this series of patients. This series further supports the need for additional research into pediatric-specific diagnostic and management criteria for PV that incorporates clinical and genetic variability."

Clinical • Cardiovascular • Dermatology • Hypertension • Myelofibrosis • Pediatrics • Polycythemia Vera • Pruritus • Thrombocytosis • Thrombosis • BCOR • CALR • EPAS1 • JAK2 • SH2B3

Clinical characteristics and outcomes in patients with SH2B3-mutated erythrocytosis: A retrospective cohort study (ASH 2025) - "Seventy-five percent (n=12) of SH2B3 -mutated patients were on either aspirin or an anticoagulant, compared to 48% (n=270) of SE and 97% (n=100) of PV patients... We identified 16 patients with SH2B3 -mutated erythrocytosis, 103 with PV, and 566 patients with SE. Baseline hemoglobin and hematocrit at diagnosis were similar between SH2B3 -mutated, SE, and PV groups (176g/L, range 160-217; 0.53L/L, range 0.48-0.66 vs. 175g/L, range 160-246; 0.52L/L, range 0.45-0.74, vs."

Retrospective data • Cardiovascular • Hematological Malignancies • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombosis • Von Hippel-Lindau Syndrome • EPOR • JAK2 • SH2B3 • VHL

Myeloproliferative neoplasms-unclassifiable (MPN-U): A carefully curated series of 30 Mayo Clinic patients (ASH 2025) - "Four (13%) patients with MPN-U experienced venous thrombo-embolic events (VTEs) including 2 with recurrent VTEs, despite active therapy with systemic anticoagulation and aspirin...Conclusion The findings from the current study were not unexpected and underline the ongoing challenges that face formal classification systems in formulating accurate diagnostic criteria for patients with MPN-U whose clinical presentation is biased by disease definitions. Regardless, it is comforting to document a favorable long-term outcome that appeared to be similar to that of ET while venous thrombosis remains a treatment challenge in both groups."

Clinical • Cardiovascular • Essential Thrombocythemia • Hematological Disorders • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis • Thrombosis • ASXL1 • CALR • JAK2 • SRSF2

Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy. (PubMed, J Am Coll Cardiol) - P3 | "In patients with STEMI treated with percutaneous coronary intervention, early aspirin withdrawal may be harmful, because it increases the risk of ischemic events. Conversely, in NSTE-ACS, potent P2Y12 inhibitor monotherapy may be a viable therapeutic option: Ischemic event rates were similar and bleeding was reduced compared with DAPT. (Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes [NEOMINDSET]; NCT04360720)."

Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

A review of immunometabolic crosstalk in PCOS-related pregnancy loss: mechanisms and emerging therapeutic strategies. (PubMed, Gynecol Endocrinol) - "Both translational and clinical for interventions with dual metabolic-immune effects are highlighted, such as metformin, antioxidants likeN-acetylcysteine, anti-androgens, and combination regimens including aspirin with low-molecular-weight heparin (LMWH). PCOS-related miscarriage is increasingly recognized as resulting from dysregulation of immune-metabolic crosstalk. Mechanism-based, multidimensional strategies targeting this dual pathology represent a promising paradigm for preventing and managing pregnancy loss in women with PCOS."

Journal • Review • Genetic Disorders • Metabolic Disorders • Obesity • Polycystic Ovary Syndrome

A clinical case study: the potential impact of maternal anti-Co4 antibody on Pregnancy Conceived by in vitro fertilization (IVF) (ASH 2025) - "Due to history of aspirin intake during pregnancy, ThromboElastoGraphy (TEG 6S) with platelet mapping assay was performed to see aspirin related platelets functional defects...Since anti-Co4 antibody is exceedingly rare and no published clinical data on the outcome and adverse reactions is available, the present clinical follow up for HTR and HDFN was of utmost importance. This case is important and ubique in the sense that the pervious three reported anti-Co4 antibodies were not associated with IVF pregnancy, or HDFN as compared to our current case where both mother and baby of IVF pregnancy were at significant risk for HTR and HDFN."

Case study • Preclinical • Gynecology • AQP1

Recurrent splenic infarction in triple-positive antiphospholipid syndrome despite therapeutic anticoagulation (ASH 2025) - "She was discharged on Apixaban. This case highlights the rarity of splenic infarction as an initial presentation of triple-positive APS. Although APS is commonly associated with thromboembolic events, splenic involvement is unusual and maybe easily overlooked. The patient's progression of infarcts, despite a therapeutic INR raised concern for possible warfarin resistance, a rare but important consideration in triple-positive APS."

Atrial Fibrillation • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Ischemic stroke • Obstetrics • Thrombocytopenia • Vasculitis

Evolving catastrophic antiphospholipid syndrome with intracerebral hemorrhage: Treatment with plasma exchange and rituximab (ASH 2025) - "Apixaban was discontinued; enoxaparin 1 mg/kg twice daily, aspirin, prednisone 1 mg/kg with taper, and rituximab 375 mg/m² weekly ×4 were initiated...He was bridged from enoxaparin to warfarin (INR goal 2–3) for indefinite anticoagulation given APS and atrial fibrillation...Given higher recurrent thrombosis with direct oral anticoagulants reported in highrisk APS, vitamin K antagonists remain preferred for longterm therapy when feasible; multidisciplinary coordination is essential to individualize immunomodulation, anticoagulant selection, and timing. Disclaimer The views expressed in this abstract are those of the author(s) and do not necessarily reflect the official policy or position of the Defense Health Agency, the Department of Defense, or the U.S. Government."

Acute Kidney Injury • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Complement-mediated Rare Disorders • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Ischemic stroke • Nephrology • Renal Disease • Thrombocytopenia • Thrombosis

Management of acute coronary syndrome and surgical revascularization in a patient with severe Hemophilia A on emicizumab (ASH 2025) - "Following an initial diagnosis of non-ST elevation myocardial infarction (MI), he received aspirin and therapeutic enoxaparin with FVIII replacement to mitigate bleeding risk. Shortly afterward, his clinical status deteriorated to an ST elevation MI, necessitating the addition of clopidogrel and use of emergent fibrinolytic therapy with further FVIII replacement to target a trough FVIII activity above 100% in the immediate post-lysis period...This case highlights the complex interplay between HA and ACS, balancing thrombotic and bleeding risks, as well as the nuances of lab monitoring for patients on emicizumab. Early identification of these high-risk patients and transfer to a facility with access to specialized laboratory monitoring and multidisciplinary care are required to optimize patient outcomes."

Clinical • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Human Immunodeficiency Virus • Infectious Disease • Myocardial Infarction • Rare Diseases • Rheumatology • Thrombosis

Extreme thrombocytosis in patients with underlying malignancy; Management, complications and outcomes. (ASH 2025) - "None of the paediatric population received aspirin or anticoagulation as thromboprophylaxis, and 4 patients (9%) had thrombotic complications...This data would also support a change in practice to consider thromboprophylaxis in patients with underlying malignancy and EXT. This real-world data has shown that thrombotic complications occurred in a higher proportion of these patients than expected, and therefore further studies are required to identify the optimal management of these patients."

Clinical • Hematological Malignancies • Infectious Disease • Lung Cancer • Mesothelioma • Myeloproliferative Neoplasm • Oncology • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Thrombocytosis • ABL1 • BCR • CALR • JAK2

Evaluating efficacy and safety of hydroxyurea and thalidomide for beta-thalassemia: A systematic review andmeta-analysis. (ASH 2025) - "The treatment regimen consisted of hydroxyurea, thalidomide and aspirin. The results have shown improved haemoglobin levels and reduced ferritin levels, while bilirubin levels showed no significant change. However, given lack of high quality data, further randomised controlled trials are required to validate these results and assess long-term outcomes."

Retrospective data • Review • Beta-Thalassemia • Genetic Disorders

Diagnosis, management, and outcomes of tumor-associated erythrocytosis: A systematic review (ASH 2025) - "Among the 79 cases of HCC, 1 patient received phlebotomies, hydroxyurea, and aspirin. TAE is a rare condition seen across several tumor types, with the most common reported in the literature being hepatocellular carcinoma and hemangioblastoma. In nearly all documented cases, resolution of erythrocytosis was achieved with definitive tumor treatment, either through surgical resection or systemic therapy. Death was primarily driven by the underlying malignancy, with few reported cases of thrombosis."

Review • Cardiovascular • Colorectal Adenocarcinoma • Colorectal Cancer • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Multiple Myeloma • Myeloproliferative Neoplasm • Oncology • Pituitary Gland Carcinoma • Plasmacytoma • Renal Cell Carcinoma • Solid Tumor • Thrombosis • Uterine Leiomyoma

Smoking and chronic kidney disease are associated with expansion of TET2 clonal hematopoiesis of indeterminate potential (CHIP) (ASH 2025) - "Utilising aprospective, extensively phenotyped cohort of older adults who were participants of the Aspirin inPreventing Events in the Elderly (ASPREE) trial, we aimed to 1) identify risk factors associated with clonegrowth and 2) determine if clone growth is related to cancer and/or mortality outcomes independent ofclone size.MethodsASPREE enrolled community-dwelling Australians ≥70 years without cardiovascular disease or 5-year life-limiting illness...Further work is required to verify these findings in different cohorts,and determine if smoking cessation or other modification of the pro-inflammatory state associated withsmoking or CKD could potentially prevent CHIP growth and adverse outcomes. Our findings that growthof CHIP was independently associated with risk of blood cancer suggest that monitoring of CHIP could beconsidered in this context."

Addiction (Opioid and Alcohol) • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hematological Malignancies • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Tobacco Cessation • ASXL1 • DNMT3A • JAK2 • KRAS • SF3B1 • TET2 • TP53

Healthcare Providers' knowledge and attitudes toward venous thromboembolism prophylaxis in multiple myeloma: A cross-sectional survey (ASH 2025) - "Among physicians, aspirin was themost prescribed VTE prophylaxis agent (55.6%), followed by direct oral anticoagulants (27.8%), low-molecular-weight heparin (11%), and warfarin (5.6%). This study reveals substantial variability in VTE risk assessment and prophylaxispractices in MM care. Although most participants exhibited moderate knowledge and positive attitudes,notable inconsistencies remain in risk stratification and clinical practice. These findings highlight the needfor targeted educational interventions and practice standardization."

Cardiovascular • Hematological Malignancies • Multiple Myeloma • Respiratory Diseases • Venous Thromboembolism

Aspirin therapy in myelofibrosis: Real-world clinical practice and outcomes in 215 consecutive patients (ASH 2025) - "Finally, a substantial symptom benefit of ASA in MF isexposed, saliently improving not only average symptom burden scores but the vast majority of sub-itemscores. Further studies are necessary to clarify the effects of ASA in MF to help guide clinical decision-making, especially in primary myelofibrosis."

Clinical • Real-world • Real-world evidence • Cardiovascular • Dermatology • Essential Thrombocythemia • Hematological Disorders • Musculoskeletal Pain • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Pruritus • Thrombocytosis • Thrombosis • CALR

Implementation challenges of the learner clinical trial in pregnant women with sickle cell disease in Angola (ASH 2025) - P1/2 | "To date, 271 severe events, 3 associated with the medication, 9 cases ofpre-eclampsia/eclampsia, 36 preterm deliveries, 5 miscarriages, 1 perinatal death, and 4 maternal deathswere registered.The current sample size is too small to draw statistically significant conclusions about the efficacy ofstarting low-dose daily aspirin earlier in pregnancy. The number of enrolled patients is below theexpected, as most pregnant women tend to seek hospital care only during the later stages of pregnancy.To ensure interventions like the LEARNER study are successfully conducted, it is urgent to invest in healthliteracy and SCD education in Angola and increase patients' awareness of the need to do prenatal andfollow-up consultations during pregnancy for the prevention of pregnancy-associated complications inwomen.The present project has the support of Calouste Gulbenkian Foundation and La Caixa FoundationCollaboration (We'Search)."

Clinical • Anemia • Genetic Disorders • Gynecology • Hematological Disorders • Obstetrics • Sickle Cell Disease

Evaluating real-world diagnostic and treatment patterns, risk of thromboembolic events, and mortality for polycythemia vera across an integrated academic-community cancer network (ASH 2025) - "At the time of analysis (07/27/2025), NAC patients with HR PVwere less likely to be on cytoreductive therapy beyond aspirin ± phlebotomy compared to those at CCC(72.9% vs 100%, p<0.0001), and more often remained on first-line (65.7% vs 25.5%, p<0.0001). In second-line, NAC patients were less likely to be on ruxolitinib (7.5% vs 21.3%) or interferons (8.8% vs 40.4%)compared to CCC patients (p<0.05 for all).At a median follow-up of 71 months, median OS was 136.4 months (95% CI: 128.0-not reached) for theentire cohort without significant difference between NAC vs CCC... Within our integrated academic-community cancer network, a greater proportion of PVpatients were treated at community sites, where patients were older and with higher risk disease by bothage and history of TEs. CCC patients were more likely to receive cytoreductive therapy and to receiveagents other than hydroxyurea for second line therapy. Despite comparable OS, NAC patients had higherrisk of..."

Clinical • Real-world • Real-world evidence • Chronic Eosinophilic Leukemia • Fibrosis • Hematological Malignancies • Immunology • Leukemia • Myeloproliferative Neoplasm • Nicotine Addiction • Oncology • Polycythemia Vera • Tobacco Addiction • JAK2

Impact of aspirin use on clinical outcomes in antiphospholipid syndrome patients with arterial thrombosis: A real-world cohort study (ASH 2025) - "In this large, real-world cohort of APS patients with arterial thrombosis, adding low-dose aspirin towarfarin was linked to a significantly higher risk of major bleeding—including gastrointestinalhemorrhage, hemoperitoneum, iron deficiency anemia, and blood transfusion—without any reduction inall-cause mortality. Importantly, rates of ischemic stroke and acute myocardial infarction were alsohigher in the aspirin group. This unexpected increase in arterial events may reflect residual confoundingby indication, as patients perceived to be at greater thrombotic risk were more likely to receivecombination therapy."

Clinical • Clinical data • Real-world • Real-world evidence • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Genetic Disorders • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Thrombosis • TINCR

Thrombocytosis in transient abnormal myelopoiesis: Association with megakaryocytic skewing and GATA1 mutation patterns (ASH 2025) - "Nothrombotic events were observed in any group, including those with platelet counts ≥1,000×10⁹/L, andonly one patient received low-dose aspirin... Thrombocytosis in TAM defines a distinct clinical and biological phenotype, characterized bymegakaryocytic skewing, inflammatory cytokine elevation, and GATA1s-high type mutations. Despitemarkedly elevated platelet counts, no thrombotic complications were observed, suggesting that TAM-associated thrombocytosis may reflect a benign, possibly functionally impaired, megakaryocyticresponse. Platelet count at diagnosis in TAM may reflect underlying disease heterogeneity, but elevatedcounts should be interpreted with caution to avoid unnecessary treatment for thrombocytosis.Importantly, transgenic mouse models expressing different levels of Gata1s confirmed that higherGata1s expression leads to increased platelet production, supporting a causal role of GATA1 mutationpattern in TAM-associated thrombocytosis."

Developmental Disorders • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • Thrombocytopenia • Thrombocytosis • CD33 • GATA1 • ITGA2B • ITGB3 • KIT • TNFA

VWF:ADAMTS13 ratio is associated with white matter hyperintensity (ASH 2025) - "Mixed effects logistic regression accountingfor family membership was used to examine the association of the VWF:ADAMTS13 ratio with any WMHand large WMH, adjusting for other clinical risk factors including age, sex, race, and the presence ofhypertension, diabetes mellitus, current smoking, total cholesterol, high-density lipoprotein (HDL)cholesterol, and aspirin use. A total of 287 participants met inclusion criteria... In conclusion, we demonstrate an association between ADAMTS13 and VWF with a strokeprecursor lesion, WMH. This provides further evidence to the growing body of literature that disruption ofthe ADAMTS13 - VWF axis may play a role in the pathogenesis of ischemic cerebrovascular disease. Ourresults may have implications for risk stratification in the general population as well as for patients withTTP in whom silent infarct and cognitive impairment remain prevalent in remission."

Alzheimer's Disease • Atherosclerosis • Cardiovascular • CNS Disorders • Cognitive Disorders • Diabetes • Hematological Disorders • Hypertension • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Vascular Neurology

Venous thromboembolism and bleeding rates in pregnant and postpartum patients with sickle cell disease (ASH 2025) - "Existing data on VTE and bleeding risks have significant limitations with a wide range ofreported VTE incidence and limited reporting of anticoagulant thromboprophylaxis or aspirin (ASA) use,SCD phenotype, and pregnancy characteristics...At the time of VTE diagnosis, 3 patients were taking ASA and 1was prescribed 40mg enoxaparin daily... Forty eligible patients with 60 pregnancies were identified and included in the analytic cohort.70% (28/40) identified as Black or African American and 18% (7/40) identified as Hispanic. Median age atdelivery was 33.8 years (IQR: 27.4-36.7), and median pre-pregnancy BMI was 24.7 kg/m2 (IQR: 22.7-28.4).Genotypes included HbSS (63%, 25/40), HbSC (23%, 9/40), HbSβ0 (8%, 3/40), HbSβ+ (5%, 2/40), andHbS/Quebec-Chori (3%, 1/40). Antepartum or postpartum thromboprophylaxis was prescribed in only15% (95% CI: 7-29%, 9/60) of pregnancies, predominantly for history of VTE (n=8/9)."

Clinical • Cardiovascular • Genetic Disorders • Hematological Disorders • Postpartum Hemorrhage • Respiratory Diseases • Sickle Cell Disease • Venous Thromboembolism